The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 2.21 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.
Charles River Laboratories International has a Altman Z-Score of 1.85, indicating it is in Grey Zones. This implies that Charles River Laboratories International is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
Charles River Laboratories International (MIL:1CRL) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International Altman Z-Score Chart
Charles River Laboratories International Annual Data
MIL:1CRL vs RVTY, QGEN, ICLR: Altman Z-Score Comparison
For the Diagnostics & Research subindustry, Charles River Laboratories International's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International Altman Z-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Charles River Laboratories International's Altman Z-Score falls into.
Charles River Laboratories International Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Charles River Laboratories International (MIL:1CRL) has a Altman Z-Score of 1.85 as of Jul. 05, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Charles River Laboratories International and its competitors. This is 29% below median its historical median of 2.62. Over the past decade, Charles River Laboratories International's Altman Z-Score has ranged from 1.88 to 3.72. According to the industry distribution chart, Charles River Laboratories International ranks #109 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 53.4%.
Is Charles River Laboratories International's Altman Z-Score too high?
Charles River Laboratories International's current Altman Z-Score of 1.85 is 29% below median its 10-year median of 2.62. Over the past 10 years, this metric has ranged from a low of 1.88 to a high of 3.72. The Medical Diagnostics & Research industry median Altman Z-Score is 2.42. Charles River Laboratories International's value of 1.85 is 23.4% below this industry median. Based on the distribution chart, Charles River Laboratories International ranks #109 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Charles River Laboratories International has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's Altman Z-Score compare to RVTY and QGEN?
According to the Medical Diagnostics & Research industry distribution chart, Charles River Laboratories International ranks #109 out of 204 companies for Altman Z-Score. This places Charles River Laboratories International in the lower half of its industry. The industry median Altman Z-Score is 2.42. Charles River Laboratories International's value of 1.85 is 23.4% below this benchmark. Historically, Charles River Laboratories International's own Altman Z-Score has ranged from 1.88 to 3.72 over the past decade. While the company's 10-year median is 2.62 vs. the industry median of 2.42, Charles River Laboratories International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Diagnostics & Research company?
The median Altman Z-Score among Medical Diagnostics & Research companies is 2.42, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Charles River Laboratories International's current Altman Z-Score of 1.85 is 23.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Charles River Laboratories International and its competitors. For the Medical Diagnostics & Research industry, the median Altman Z-Score is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Charles River Laboratories International's current Altman Z-Score is 1.85, which is 29% below median its own 10-year median of 2.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Charles River Laboratories International (MIL:1CRL) has a current Altman Z-Score of 1.85. The stock's GF Value™ is €121.29, compared to a current price of €143.90 — trading 18.6% above its estimated fair value. The current Altman Z-Score is 1.85, which is 29% below median its 10-year median of 2.62 and 23.4% below the Medical Diagnostics & Research industry median of 2.42. Charles River Laboratories International's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Charles River Laboratories International (MIL:1CRL), the current Altman Z-Score is 1.85 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Charles River Laboratories International (MIL:1CRL) Overvalued in 2026?
Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued.
The current stock price of €143.90 is trading 18.6% above its estimated GF Value™ of €121.29.
Key valuation signals for MIL:1CRL:
Altman Z-Score: 1.85 (29% below median its 10-year median of 2.62)
GF Value™: €121.29 vs. price of €143.90 (18.6% above fair value)
Industry Position: 23.4% below the Medical Diagnostics & Research median (#109 of 204)
No single metric tells the full story. See the MIL:1CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Charles River Laboratories International Business Description
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
70GF Score
Get the complete analysis for MIL:1CRL
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1CRL has been successfully added to your 
